The Medicines Company was incorporated in Delaware on July 31, 1996. The Company is a global biopharmaceutical company focused on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on 3,000 acute and intensive care hospitals worldwide. The Company markets products including; Angiomax (bivalirudin), Recothrom Thrombin, topical (Recombinant), Cleviprex (clevidipine) injectable emulsion and Minocin IV (Minocycline for Injection). Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding. Cleviprex is an intravenous small molecule calcium channel blocker. Minocin IV is an Tetracycline-class antibiotic used for treatment of bacterial infections caused by Acinetobacter species. The Company has a pipeline of acute and intensive care hospital products in development, including five registration stage product candidates; cangrelor, oritavancin, IONSYSTM (fentanyl iontophoretic transdermal system), Fibrocaps and RPX-602, and three research and development product candidates, MDCO-216, CarbavanceTM and ALN-PCSsc. In addition to these products and product candidates company also sells a ready-to-use formulation of Argatroban and have a portfolio of ten generic drugs, referred to as acute care generic products, that have the non-exclusive right to market in the United States. The Company is currently selling three of its acute care generic products, midazolam, ondansetron and rocuronium; and also co-promote the oral tablet antiplatelet medicine BRILINTA (ticagrelor) in the United States as part of global collaboration agreement with AstraZeneca LP and the Boston Scientific Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, or the Promus PREMIER Stent System, in the United States under its co-promotion agreement with Boston Scientific Corporation, or BSX. It faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The Company and its customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which it may conduct its business. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products.